Document:

Recission & Settlement Agreement

         This Recission  Agreement (the "Agreement") is made and entered into by
and among AmeriNet Group.com,  Inc., a publicly held Delaware corporation with a
class  of  securities  registered  under  Section  12(g)  of  the  Exchange  Act
("AmeriNet"), Vista Vacations International, Inc., a Florida corporation ("Vista
Vacations"),  Teri Nadler, Scott Ugell, Jean Hickman, Ken & Carol Nelson, Alicia
Torrealba,   Karyn  McKnight  and  Nellie  Tippery   (collectively   the  "Vista
Individuals").

                                    Preamble:

         WHEREAS, on March 12, 2000 AmeriNet and Vista Vacations participated in
a reorganization pursuant to Code Section 368(a)(2)(D),  pursuant to which Vista
Vacations  became  a  wholly  owned  subsidiary  of  AmeriNet  and all of  Vista
Vacation's  capital stock, being 1,265 shares of common stock were exchanged for
220,000  shares  of  AmeriNet  common  which  were  to be  issued  to the  Vista
Individuals other than Nellie Tippery; and

         WHEREAS,  pursuant to the  reorganization,  AmeriNet  was also to issue
66,667 shares of AmeriNet  common stock to Nellie  Tippery,  a creditor of Vista
Vacations; and,

         WHEREAS,  AmeriNet has loaned Vista Vacations $135,000 in expansion and
operating funds since the reorganization (the "AmeriNet Loans"); and,

         WHEREAS, disagreements have arisen between AmeriNet and Vista Vacations
such that the parties  believe that it is their mutual best  interest to rescind
the reorganization ,and,

         WHEREAS,  AmeriNet  has  elected  to  acquire  20%  of the  issued  and
outstanding  stock of Vista  Vacations  in  exchange  for the  discharge  of the
AmeriNet Loans,

         NOW,  THEREFORE,  in  consideration  of  the  covenants,  promises  and
representations set forth herein, and for other good and valuable consideration,
the Parties, intending to be legally bound, hereby agree as follows:

                                   Witnesseth:

                                    Article I
                                   Definitions

         The following terms or phrases,  as used in this Agreement,  shall have
the following meanings:

(A)  Accredited Investor:

               An  investor  that meets the  requirements  for  treatment  as an
               accredited  investor,  as  defined in Rule  501(a) of  Commission
               Regulation D, which provides as follows:

               Accredited investor.  "Accredited investor" shall mean any person
               who comes  within  any of the  following  categories,  or who the
               issuer  reasonably  believes  comes  within any of the  following
               categories,  at the  time of the sale of the  securities  to that
               person:

                                     Page 4
<PAGE>

               (1)  Any bank as defined in  section  3(a)(2) of the Act,  or any
                    savings and loan association or other institution as defined
                    in  section  3(a)(5)(A)  of the Act  whether  acting  in its
                    individual  or  fiduciary  capacity;  any  broker  or dealer
                    registered pursuant to section 15 of the Securities Exchange
                    Act of 1934;  any  insurance  company  as defined in section
                    2(13) of the Act; any investment  company  registered  under
                    the Investment Company Act of 1940 or a business development
                    company as defined in section  2(a)(48)  of that Act;  Small
                    Business  Investment  Company  licensed  by the  U.S.  Small
                    Business  Administration  under section 301(c) or (d) of the
                    Small Business  Investment Act of 1958; any plan established
                    and maintained by a state,  its political  subdivisions,  or
                    any agency or  instrumentality  of a state or its  political
                    subdivisions for the benefit of its employees,  if such plan
                    has total assets in excess of $5,000,000;  employee  benefit
                    plan within the meaning of the  Employee  Retirement  Income
                    Security Act of 1974 if the investment decision is made by a
                    plan  fiduciary,  as defined  in section  3(21) of such Act,
                    which  is  either  a bank,  savings  and  loan  association,
                    insurance company,  or registered  investment adviser, or if
                    the  employee  benefit  plan has  total  assets in excess of
                    $5,000,000  or, if a  self-directed  plan,  with  investment
                    decisions   made  solely  by  persons  that  are  accredited
                    investors;

               (2)  Any  private  business  development  company  as  defined in
                    section 202(a)(22) of the Investment Advisers Act of 1940;

               (3)  Any  organization  described  in  Section  501(c)(3)  of the
                    Internal Revenue Code, corporation, Massachusetts or similar
                    business trust, or partnership,  not formed for the specific
                    purpose of  acquiring  the  securities  offered,  with total
                    assets in excess of $5,000,000;

               (4)  Any director,  executive officer,  or general partner of the
                    issuer  of the  securities  being  offered  or sold,  or any
                    director, executive officer, or general partner of a general
                    partner of that issuer;

               (5)  Any natural person whose  individual net worth, or joint net
                    worth with that person's spouse, at the time of his purchase
                    exceeds $1,000,000;

               (6)  Any natural person who had an individual income in excess of
                    $200,000  in each of the two  most  recent  years  or  joint
                    income  with that  person's  spouse in excess of $300,000 in
                    each of those  years  and has a  reasonable  expectation  of
                    reaching the same income level in the current year;

               (7)  Any trust,  with total assets in excess of  $5,000,000,  not
                    formed for the specific  purpose of acquiring the securities
                    offered,  whose  purchase  is  directed  by a  sophisticated
                    person as described in ss.230.506(b)(2)(ii); and

               (8)  Any entity in which all of the equity owners are  accredited
                    investors.

(B)(1) Closing:     The  effectuation  of the  transactions  called  for by this
                    Agreement,  including  exchange of securities,  execution of
                    instruments, stock certificates,  stock powers, releases and
                    other documents.

   (2)Closing Date: The date on which the Closing takes place.

(C)  Code:          The Internal Revenue Code of 1986, as amended.

                                     Page 5
<PAGE>

(D)  Commission:    The United States Securities and Exchange Commission

(E)  EDGAR:         The  Commission's  electronic  data  gathering and retrieval
                    system accessible by the public at the Commission's  website
                    located at http://www.sec.gov.

(F)  Exchange Act:  The Securities Exchange Act of 1934, as amended.

(G)  Exchange Act Reports:

                    The reports on Commission  Forms 10-SB,  10-KSB,  10-QSB and
                    8-K and  Commission  Schedules 14A and 14C, that AmeriNet is
                    required  to file  pursuant to  Sections  13, 14,  15(d) and
                    12(g) of the Exchange Act.

(H) Florida Act:    The Florida Securities and Investor Protection Act

(I) Florida Rule:   Florida  Rule   3E-500.005,   which   provides  as  follows:
                    Disclosure requirements of Section 517.061(11)(a)3., Florida
                    Statutes.

          (1)  Transactions  by an  issuer  which  do  not  satisfy  all  of the
          conditions  of this rule  shall not  raise  any  presumption  that the
          exemptions  provided by Section  517.061(11),  Florida Statutes is not
          available for such transactions.  Attempted  compliance with this rule
          does  not  act  as  an  election;   the  issuer  can  also  claim  the
          availability of Section  517.061(11),  Florida Statutes,  outside this
          rule.

          (2) The determination as to whether sales of securities are part of a
              larger  offering (i.e.,  are deemed to be integrated)  depends on
              the particular facts and  circumstances.  In determining  whether
              sales  should be regarded as part of a larger  offering  and thus
              should be  integrated,  the  facts  described  in Rule  3E-500.01
              should be considered.

          (3) Although  sales made  pursuant  to Section  517.061(11),  Florida
              Statutes,  and in compliance  with this rule, are exempt from the
              registration  provisions  of this Act,  such  exemption  does not
              avoid the antifraud  provisions of Sections  517.301 and 517.311,
              Florida Statutes.

          (4) The  provisions  of this rule shall  apply  only to  transactions
              which are consummated with persons in the State of Florida.

          (5) The requirements of Sections 517.061(11)(a)(3), Florida Statutes,
              that each purchaser,  or his  representative  be provided with or
              given  reasonable  access  to full  and  fair  disclosure  of all
              material  information  shall be deemed to be  satisfied if either
              paragraphs (5)(a) or (5)(b) are complied with:

              (a) Access to or Furnishing of  Information.  Reasonable  access
                  to, or the  furnishing  of,  material  information  shall be
                  deemed  to  have  been  satisfied  if  prior  to the  sale a
                  purchaser is given access to the following information:

                  1. All material books and records of the issuer; and

                  2. All  material   contracts  and  documents  relating  to the
                    proposed transaction; and

                  3. An  opportunity  to  question  the   appropriate  executive
                     officers or partners. ....

                                     Page 6

<PAGE>

          (6)  In the case of an issuer  that is subject  to the  reporting
               requirements  of  Section  13 or  15(d)  of  the  Securities
               Exchange Act of 1934, the provisions of paragraph  (5)(b) of
               this  rule  shall  be  deemed  satisfied  by  providing  the
               following:

              (a)   The  information  contained in the annual report required to
                    be filed  under  the  Securities  Exchange  Act of 1934 or a
                    registration  statement on Form S-1 [CCH Federal  Securities
                    Law  Reporter  P. 7121 ] under the  Securities  Act of 1933,
                    whichever  filing is the most  recent  required to be filed,
                    and  the  information  contained  in  any  definitive  proxy
                    statement required to be filed pursuant to Section 14 of the
                    Securities  Exchange  Act of  1934  and in  any  reports  or
                    documents  required  to be filed by the issuer  pursuant  to
                    Section  13(a) or 15(d) of the  Securities  Exchange  Act of
                    1934, since the filing of such annual report or registration
                    statement; and

               (b)  A brief description of the securities being offered, the use
                    of the proceeds from the offering,  and any material changes
                    in the  issuer's  affairs  which  are not  disclosed  in the
                    documents furnished.

(J) Reorganization: The  corporate   events  effected  in  reliance  on  Section
                    368(a)(2)(D)  of the Code which took place on or about March
                    12, 2000 between AmeriNet and Vista  Vacations,  as a result
                    of which Vista Vacations became a wholly owned subsidiary of
                    AmeriNet  and  Ms.  Nadler,  Mr.  Ugell,  Ms.  Hickman,  Ms.
                    Torrealba, Ms. McKnight, Mr. And Mrs. Nelson and Ms. Tippery
                    were to become AmeriNet shareholders.

(K) Reorganization Agreement:

                    The  agreement  between  AmeriNet  and  all  of  the  former
                    stockholders of Vista Vacations closed on or about March 12,
                    2000,  pursuant to which  Vista  Vacations  securities  were
                    exchanged for AmeriNet securities and Vista Vacations became
                    a  wholly  owned  subsidiary  of  AmeriNet,  a  copy  of the
                    Reorganization   Agreement   having   been  filed  with  the
                    Commission at its EDGAR website.

(L) Securities Act: The Securities Act of 1933, as amended.

(M)  Service:    The United States Internal Revenue Service.

(N)  All undefined  financial terms shall have the meanings  ascribed to them by
     generally accepted accounting practices,  consistently applied, as modified
     by rules of the Commission.

(O)  Additional  terms  characterized  by initial capital letters are defined in
     this Agreement immediately following their first use.

                                     Page 7
<PAGE>
                                   Article II
                              Operative Provisions

         Subject to the  condition  precedent  that all  actions  required to be
taken in order to comply with the securities and other laws of each state having
jurisdiction over the transactions called for under this Agreement,  the Parties
hereby agree as follows:

(A)  In consideration  for the Agreements of AmeriNet in Sections 2(A) and 2(B),
     Vista Vacations and the Vista Individuals hereby agree to :

         (1)      Issue  20 % of the  issued  and  outstanding  stock  in  Vista
                  Vacations to AmeriNet in exchange for AmeriNet's  discharge of
                  the AmeriNet Loans as provided in Section 2 (B)(1).

         (2)      Vote the proxy granted to it by AmeriNet in Section (2) (B)(3)
                  as a fiduciary,  based solely on consideration  for AmeriNet's
                  best interests as a minority shareholder of Vista Vacations.

         (3)      Maintain  timely  and bona  fide  financial  records,  provide
                  copies of annual financial  statements to AmeriNet on a timely
                  basis,  to be certified  if Vista  Vacations is in a financial
                  position to do so, and allow  AmeriNet  access to review Vista
                  Vacations  financial  records on a periodic  basis in a manner
                  that will not cause interruption of Vista Vacations' business.

         (4)      Refrain from engaging in any corporate action that would cause
                  harm to AmeriNet's interest in Vista Vacations, including, but
                  not limited to, selling Vista Vacations in a non-arm's  length
                  transaction,  causing  Vista  Vacations  to become  insolvent,
                  paying  employees  salaries  or  other  benefits  that are not
                  consistent  with  their  current  employment   agreements  and
                  reasonable  considering Vista Vacations  financial  condition,
                  and  diluting  AmeriNet's  interest  in Vista  Vacations,  all
                  without the prior consent of AmeriNet; provided, however, this
                  paragraph shall not apply to Vista Vacation's  insolvency as a
                  result of it being unable to acquire  adequate  funding within
                  30 days hereof after making a good faith attempt to do so.

         (5)      To  refrain  from  taking any  action  that  would  violate or
                  facilitate  the violation of any of the provisions of Sections
                  2(A) and 2(B) of this Agreement;

         (6)      Release  AmeriNet  and its  affiliates,  and its  consultants,
                  including The Yankee Companies,  from any obligations to them,
                  from  the   beginning  of  time  until  the  Closing  on  this
                  Agreement,  other than the obligations specifically undertaken
                  by AmeriNet.

(B)  In  consideration  for  Ms.  Nadler's,  Mr.  Ugell's,  Ms.  Hickman's,  Ms.
     Torrealba's, Mr. Nelson's, Ms. McKnight's and Ms. Tippery's return of their
     AmeriNet  shares,  the covenants of Vista Vacations set forth below and the
     other  actions  performed  or to be performed  by and Vista  Vacations,  as
     required by this Agreement, AmeriNet hereby agrees to and does hereby:

         (1)   Discharge  the  AmeriNet  Loans  in  exchange  for the 20% of the
               issued and outstanding stock of Vista Vacations.

         (2)   Return one  hundred  percent  (100%) of the  securities  of Vista
               Vacations  which  were  received  by  AmeriNet  pursuant  to  the
               reorganization.

                                     Page 8
<PAGE>

         (3)   Grant Ms.  Nadler and Mr. Ugell a proxy to vote all of AmeriNet's
               capital  stock  in  Vista  Vacations  in  accordance  with  their
               obligation as set forth in paragraph (2) (A)(5) .

         (4)   Release  Vista   Vacations  and  its  affiliates  and  the  Vista
               Individuals  from any  obligations to them, from the beginning of
               time  until  the  Closing  on  this  Agreement,  other  than  the
               obligations  specifically  undertaken pursuant to this Agreement;
               and

(C)      As a material  inducement  to each Parties  entry into this  Agreement,
         each  of  the  Parties  hereby   represents  to  the  others  that  the
         representing Party:

         (1)      Is  familiar  with  the   requirements  for  treatment  as  an
                  "accredited  investor" under  Regulation D and Section 4(6) of
                  the Securities Act and meets one or more of the definitions of
                  an "accredited  investor" contained in Rule 501(a) promulgated
                  under  authority of Securities  Act and has, alone or together
                  with his, her or its advisors or representatives, if any, such
                  knowledge and  experience in financial  matters that he she or
                  it is capable of evaluating  the relative  risks and merits of
                  the transactions  contemplated hereby, the text of Rule 501(a)
                  being set forth, in full, above;

         (2)      Acknowledges  that he, she or it has, based on his, her or its
                  own  substantial  experience,  the  ability  to  evaluate  the
                  transactions  contemplated  hereby  and the  merits  and risks
                  thereof in general and the  suitability of the transaction for
                  him, her or it in particular;

         (3)      (a)      Understands   that   the   offer   and   transfer  or
                           issuance of the securities  involved is being made in
                           reliance on the Party's  representation  that he, she
                           or it has reviewed all of  AmeriNet's  reports  filed
                           with the  Commission  during  the past 12 months  and
                           posted  on  the   Commission's   Internet   web  site
                           (www.sec.gov)  under the EDGAR Archives sub site, and
                           has become  familiar with the  information  disclosed
                           therein,  including  that contained in exhibits filed
                           with such reports;

                  (b)      Is fully aware of the material risks  associated with
                           becoming an investor in Vista  Vacations and confirms
                           that he, she or it was  previously  informed that all
                           documents,  records  and  books  pertaining  to  this
                           investment  have been available from Vista  Vacations
                           and that all documents,  records and books pertaining
                           to this transaction  requested by him, her or it have
                           been made available to him, her or it;

         (4)      Has had an opportunity to ask questions of and receive answers
                  from the officers of Vista Vacations  concerning the terms and
                  conditions of this Agreement and the transactions contemplated
                  hereby,  as  well  as the  affairs  of  Vista  Vacations,  the
                  contemplated affairs of Vista Vacations and related matters;

                                     Page 9
<PAGE>

         (5)      Has  had  an  opportunity  to  obtain  additional  information
                  necessary to verify the accuracy of the  information  referred
                  to in subparagraphs  (a), (b), (c) and (d) hereof,  as well as
                  to  supplement  the  information  in the  Exchange Act Reports
                  called for by the Florida Rule;

         (6)      Has  represented that he, she or it has the general ability to
                  bear  the risks of the subject transaction and that he, she or
                  it is a suitable investor for a private offering;

         (7)      Is aware that:

                  (a)      The securities involved are a speculative  investment
                           with  no  assurance  that  Vista  Vacations  will  be
                           successful, or if successful,  that such success will
                           result in payments to such Party or to realization of
                           capital  gains by such  Party on  disposition  of the
                           securities involved; and

                  (b)      The  securities  to be issued to him,  her or it have
                           not been registered under the Securities Act or under
                           any state securities laws, accordingly such Party may
                           have to hold such  securities  and may not be able to
                           liquidate,  pledge,  hypothecate,  assign or transfer
                           them;

                                   Article III
                      Recission, Mutual Releases & Closing

(A)      The terms of this Agreement supersede the terms of all other agreements
         between AmeriNet and Vista Vacations and their affiliates, all of which
         will be  henceforth  null and void as if they had  never  been  entered
         into,  this Agreement  being deemed a novation,  settlement  accord and
         satisfaction of all such prior agreements.

(B)      In  consideration  for the  exchange of covenants  reflected  above but
         excepting only the obligations created by this Agreement, AmeriNet, and
         Vista Vacations  hereby each release,  discharge and forgive the other,
         and each of the others' subsidiaries,  affiliates,  members,  officers,
         directors, partners, agents and employees from any and all liabilities,
         whether current or inchoate,  from the beginning of time until the date
         of this Agreement.

(C)      In  consideration  for the  exchange of covenants  reflected  above but
         excepting only the obligations created by this Agreement, AmeriNet, and
         the Vista  Individuals  hereby each release,  discharge and forgive the
         other,  and  each of the  others'  subsidiaries,  affiliates,  members,
         officers,  directors,  partners,  agents and employees from any and all
         liabilities,  whether  current or inchoate,  from the beginning of time
         until the date of this Agreement.

(D)      The transactions contemplated by this Agreement, issuance of the equity
         interests  in Vista  Vacations  shall be  effected  as soon as possible
         following the execution of this  Agreement,  but in any event, no later
         than June 30,

                                      Page 10

<PAGE>

         2000,  and,  to the extent  possible,  the  Closing  shall be  effected
         through  exchange of documents and  instruments in escrow,  by next day
         delivery  service,  such documents and  instruments to be released from
         escrow  concurrently  with  confirmation  by  legal  counsel  to  Vista
         Vacations  and  Amerinet  that all  transactions  contemplated  by this
         Agreement have been completed.

                                   Article IV
                               General Provisions

4.1      Interpretation.

(A)      When a reference  is made in this  Agreement  to schedules or exhibits,
         such  reference  shall be to a schedule  or  exhibit to this  Agreement
         unless otherwise indicated.

(B)      The words "include,"  "includes" and "including" when used herein shall
         be  deemed  in  each  case  to  be  followed  by  the  words   "without
         limitation."

(C)      The headings  contained in this  Agreement are for  reference  purposes
         only and shall not affect in any way the meaning or  interpretation  of
         this Agreement.

(D)      The captions in this Agreement are for  convenience  and reference only
         and in no way  define,  describe,  extend  or limit  the  scope of this
         Agreement or the intent of any provisions hereof.

(E)      All pronouns and any variations thereof shall be deemed to refer to the
         masculine, feminine, neuter, singular or plural, as the identity of the
         Party or Parties,  or their  personal  representatives,  successors and
         assigns may require.

(F)      The Parties agree that they have been represented by counsel during the
         negotiation and execution of this Agreement and,  therefore,  waive the
         application  of any law,  regulation,  holding or rule of  construction
         providing  that  ambiguities  in an agreement or other document will be
         construed against the party drafting such agreement or document.

4.2      Notice.

(A)      All notices,  demands or other  communications given hereunder shall be
         in  writing  and shall be  deemed to have been duly  given on the first
         business day after  mailing by United  States  registered  or certified
         mail, return receipt requested, postage prepaid, addressed as follows:

         (1)      To AmeriNet:

                            AmeriNet Group.com, Inc.
        Crystal Corporate Center; 2500 North Military Trail, Suite 225-C;
                           Boca Raton, Florida 33431
                   Attention: Lawrence R. Van Etten, President

        (2)      To Vista Vacations:

                       Vista VacationsInternational, Inc.
                   5653 NW 29th Street, Margate, Florida 33063
                        Attention: Teri Nadler, President

                                    Page 11
<PAGE>

         (3)      To the Vista Individuals:

                              Scott Ugell, Esquire
                 155 North Main Street, New City, New York 10956

         or such  other  address  or to such  other  person as any  Party  shall
         designate to the other for such purpose in the manner  hereinafter  set
         forth.

(B)      At the request of any Party,  notice will also be provided by overnight
         delivery,   facsimile   transmission   or  e-mail,   provided   that  a
         transmission receipt is retained.

(C)      (1)      Amerinet  acknowledge  that  the  Yankee   Companies,  Inc., a
                  Florida   corporation   ("Yankees")   serves  as  a  strategic
                  consultant to AmeriNet and has acted as scrivener for Amerinet
                  in this transaction but that Yankees is neither a law firm nor
                  an agency subject to any professional regulation or oversight.

         (2)      Yankees has advised Amerinet to retain  independent  legal and
                  accounting  counsel to review this  Agreement and its exhibits
                  and incorporated materials on their behalf.

         (3)      The  decision  by  Amerinet  not to use the  services of legal
                  counsel in conjunction with this  transaction  shall be solely
                  at their  own risk,  Amerinet  acknowledging  that  applicable
                  rules of the Florida Bar prevent  AmeriNet's  general counsel,
                  who has reviewed,  approved and caused modifications on behalf
                  of AmeriNet,  from representing  anyone other than AmeriNet in
                  this transaction.

4.3      Merger of All Prior Agreements Herein.

(A)      This  instrument,  together  with the  instruments  referred to herein,
         contains all of the  understandings  and agreements of the Parties with
         respect to the subject matter discussed herein.

(B)      All prior  agreements  whether  written  or  oral are merged herein and
         shall be of no force or effect.

4.4      Survival.

         The several  representations,  warranties  and covenants of the Parties
contained herein shall survive the execution hereof and the  Reorganization  and
shall be effective  regardless of any  investigation  that may have been made or
may be made by or on behalf of any Party.

4.5      Severability.

         If any  provision or any portion of any  provision  of this  Agreement,
other than one of the conditions precedent or subsequent,  or the application of
such  provision or any portion  thereof to any person or  circumstance  shall be
held invalid or unenforceable,  the remaining portions of such provision and the
remaining  provisions of this Agreement or the  application of such provision or
portion of such  provision  as is held  invalid or  unenforceable  to persons or
circumstances  other  than those to which it is held  invalid or  unenforceable,
shall not be affected thereby.

                                    Page 12
<PAGE>

4.6      Governing Law.

         This Agreement  shall be construed in accordance  with the  substantive
and  procedural  laws of the State of  Delaware  (other  than  those  regulating
taxation and choice of law).

4.7      Indemnification.

(A)      Each Party hereby  irrevocably  agrees to indemnify  and hold the other
         Parties  harmless from any and all liabilities  and damages  (including
         legal or other expenses incidental  thereto),  contingent,  current, or
         inchoate  to which  they or any one of them  may  become  subject  as a
         direct,  indirect  or  incidental  consequence  of  any  action  by the
         indemnifying   Party  or  as  a  consequence  of  the  failure  of  the
         indemnifying  Party to act,  whether  pursuant to  requirements of this
         Agreement or otherwise.

(B)      In the event it becomes  necessary to enforce this indemnity through an
         attorney,  with or without  litigation,  the successful  Party shall be
         entitled to recover from the  indemnifying  Party,  all costs  incurred
         including  reasonable  attorneys'  fees  throughout  any  negotiations,
         trials or appeals, whether or not any suit is instituted.

4.8      Dispute Resolution.

(A)      In any action  between  the Parties to enforce any of the terms of this
         Agreement  or  any  other  matter   arising  from  this  Agreement  any
         proceedings   pertaining  directly  or  indirectly  to  the  rights  or
         obligations  of the  Parties  hereunder  shall,  to the extent  legally
         permitted,  be held in Palm Beach County,  Florida,  and the prevailing
         Party shall be entitled  to recover its costs and  expenses,  including
         reasonable attorneys' fees up to and including all negotiations, trials
         and appeals, whether or not any formal proceedings are initiated.

(B)      In the  event of any  dispute  arising  under  this  Agreement,  or the
         negotiation  thereof or inducements  to enter into the  Agreement,  the
         dispute shall,  at the request of any Party,  be  exclusively  resolved
         through the following procedures:

         (1)      (a)      First,  the  issue  shall  be  submitted to mediation
                           before a  mediation  service  in Palm  Beach  County,
                           Florida to be selected by lot from four  alternatives
                           to be provided,  two Vista Vacations and/or the Vista
                           Individuals and two by AmeriNet .

                  (b)      The mediation  efforts shall be concluded  within ten
                           business  days  after  their  initiation  unless  the
                           Parties  unanimously  agree to an extended  mediation
                           period;

         (2)      In the event that  mediation  does not lead to a resolution of
                  the  dispute  then at the  request of any Party,  the  Parties
                  shall  submit the  dispute to  binding  arbitration  before an
                  arbitration  service located in Palm Beach County,  Florida to
                  be selected by lot, from four alternatives to be provided, two
                  by Vista  Vacations  and/or the Vista  Individuals  and two by
                  AmeriNet.

                                    Page 13
<PAGE>

         (3)      (a)      Expenses  of  mediation shall be borne equally by the
                           Parties, if successful.

                  (b)      Expenses  of  mediation,   if  unsuccessful   and  of
                           arbitration  shall be borne by the  Party or  Parties
                           against whom the arbitration decision is rendered.

                  (c)      If the terms of the arbitral award do not establish a
                           prevailing  Party,  then the expenses of unsuccessful
                           mediation and  arbitration  shall be borne equally by
                           the Parties involved.

4.9      Benefit of Agreement.

         The terms and  provisions of this  Agreement  shall be binding upon and
inure  to the  benefit  of the  Parties,  their  successors,  assigns,  personal
representatives,  estate, heirs and legatees but are not intended to confer upon
any other person any rights or remedies hereunder.

4.10     Further Assurances.

         The Parties agree to do,  execute,  acknowledge and deliver or cause to
be done,  executed,  acknowledged  or delivered and to perform all such acts and
deliver all such deeds, assignments, transfers, conveyances, powers of attorney,
assurances,  stock certificates and other documents,  as may, from time to time,
be required herein to effect the intent and purpose of this Agreement.

4.11     Counterparts.

(A)      This Agreement may be executed in any number of counterparts.

(B)      All   executed    counterparts    shall    constitute   one   Agreement
         notwithstanding  that  all  signatories  are  not  signatories  to  the
         original or the same counterpart.

(C)      Execution by exchange of facsimile transmission shall be deemed legally
         sufficient  to bind the  signatory;  however,  the Parties  shall,  for
         aesthetic  purposes,  prepare a fully executed original version of this
         Agreement which shall be the document filed with the Commission.

4.12     License.

(A)      This  form of  agreement  is the  property  of  Yankees  and  has  been
         customized for this transaction with the consent of Yankees.

(B) The use of this form of agreement by the Parties is authorized hereby solely
for purposes of this transaction.

(C)      The use of this form of agreement or of any derivation  thereof without
         Yankees' prior written permission is prohibited.

                                      Page 14

<PAGE>

     In Witness Whereof,  AmeriNet, Vista Vacations and Ms. Nadler and Mr. Ugell
have caused this Agreement to be executed by themselves or their duly authorized
respective officers, all as of the last date set forth below:

Signed, Sealed and Delivered
         In Our Presence:

                                                        AmeriNet Group.com, Inc.

_________________________________                       (A Delaware corporation)

_________________________________         By:    /s/ Lawrence R. Van Etten
                                                 _____________________________
                                                Lawrence R. Van Etten, President
         (Corporate Seal)

                                          Attest: /s/ Vanessa H. Lindsey
                                                  _____________________________
                                                   Vanessa H. Lindsey, Secretary
Dated:   June 30, 2000

State of Florida           }
County of Palm Beach       } ss.:

         On this 30th day of June,  2000,  before me, a notary public in and for
the county and state aforesaid,  personally  appeared  Lawrence R. Van Etten and
Vanessa  H.  Lindsey,  to me  known,  and  known to me to be the  president  and
secretary of AmeriNet Group.com, Inc., the above-described  corporation,  and to
me  known  to  be  the  persons  who  executed  the  foregoing  instrument,  and
acknowledged  the execution  thereof to be their free act and deed, and the free
act and deed of AmeriNet  Group.com,  Inc.,  for the uses and  purposes  therein
mentioned.

         In witness whereof, I have hereunto set my hand and affixed my notarial
seal the day and year in this  certificate  first above  written.  My commission
expires the ___day of ______________, ____.

         {Seal}
                                                --------------------------------
                                                         Notary Public

                                             Vista Vacations International, Inc.

_________________________________                    (a Florida corporation)

_________________________________         By:   /s/ Teri Nadler
                                                 _____________________________
                                                     Teri Nadler, President

         (Corporate Seal)

                                         Attest: /s/ Alicia Torrealba
                                                _____________________________
                                                    Alicia Torrealba, Secretary

Dated:   June 30, 2000

State of Florida           }
County of Palm Beach       } ss.:

         On this 30th day of June,  2000,  before me, a notary public in and for
the  county  and state  aforesaid,  personally  appeared  Ter  Nadler and Alicia
Torrealba,  to me known,  and known to me to be the  president  and secretary of
Vista Vacations International,  Inc., the above-described corporation, and to me
known to be the persons who executed the foregoing instrument,  and acknowledged
the execution  thereof to be their free act and deed,  and the free act and deed
of Vacations International, Inc., for the uses and purposes therein mentioned.

                  In witness whereof, I have hereunto set my hand and affixed my
notarial  seal the day and year in this  certificate  first  above  written.  My
commission expires the ___day of ______________, ____.

         {Seal}
                                      ----------------------------
                                       Notary Public

                                      Page  15

<PAGE>

                                               Scott Ugell, as Attorney-in-Fact
                                                      For the Vista Individuals

---------------------------------
                                                   /s/ Scott Ugell
---------------------------------                 -----------------------------

Dated:   June 30, 2000

State of New York          }
County of Rockland         } ss.:

         On this 30th day of June,  2000,  before me, a notary public in and for
the county and state aforesaid,  personally  appeared Scott Ugell known to me to
be the person who  executed  the  foregoing  instrument,  and  acknowledged  the
execution thereof to be his free act and deed, for the uses and purposes therein
mentioned.

                  In witness whereof, I have hereunto set my hand and affixed my
notarial  seal the day and year in this  certificate  first  above  written.  My
commission expires the ___day of ______________, ____.

         {Seal}
                                                  ----------------------------
                                                             Notary Public

Also have sigend signature pages for Teri Nadler, Scott Ugell, Jean Hickman,
Karyn McKnight, Alicia Torrealba, Nellie Tippery, Kenneth & Carol Nelson.

                                    Page 16"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

                         RESEARCH AND LICENSE AGREEMENT

This  License  Agreement  ("Agreement"),  effective  as of 28th day of May, 1999
("Effective  Date")  is  by and between Novo Nordisk A/S, a corporation existing
under  the laws of Denmark and having a place of business at Novo Alle, DK-2880,
Bagsvaerd,  Denmark  ("Novo  Nordisk"),  and DGI BioTechnologies, LLC, a company
having  its principal place of business at 40 Talmadge Road, PO Box 424, Edison,
NJ  08818-0424.

                                   WITNESSETH

     WHEREAS,  DGI  is  the  owner  of  certain  DGI  Technology (as hereinafter
defined)  and  DGI  Patent  Rights  (as  hereinafter  defined);  and

     WHEREAS,  Novo Nordisk desires to obtain from DGI, and DGI desires to grant
to Novo Nordisk a license to use and sell products in all countries of the world
under  such  DGI  Patent  Rights  and  DGI  Technology.

     NOW  THEREFORE,  in  consideration of the mutual promises and for the other
good  and  valuable  consideration, the receipt of which is hereby acknowledged,
the  Parties  agree  as  follows:

1.   DEFINITIONS

The  following  definitions  shall  control  the  construction  of  each  of the
following  items  wherever  they  appear  in  this  Agreement.

1.1     "Affiliate"  shall mean any company, joint venture partnership, or other
business  entity  which  controls,  is controlled by, or is under common control
with DGI or Novo Nordisk, as the case may be.  A business entity shall be deemed
to  control another business entity if it possesses, directly or indirectly, the
power  to  order  or  cause the direction, management and policies of such other
business entity, whether through the ownership of voting securities, by contract
or  otherwise.

1.2     "DGI"  shall mean DGI BioTechnologies, LLC and/or any Affiliate which is
a  party  to  the  arrangements  set  forth  in  this  Agreement.

1.3     "DGI Patent Rights" shall mean all of DGI's rights possessed at any time
during the Term of this Agreement in and to any patents and patent applications,
including but not limited to DGI patents listed on Appendix A to this Agreement.
Said  patents  and  patent  applications  shall  include  but  not be limited to
selection  patents,  patent  applications,  divisionals,  continuations,
continuations-in-part,  reissues,

                                      1
<PAGE>

"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

re-examinations  and  extensions.  Extensions  of  patents  shall  include;  (a)
extensions under the U.S. Patent Term Restoration Act, (b) extensions of patents
under Japanese Patent Law, (c) Supplementary Protection Certificates for members
of  the  European Patent Convention and other countries in the European Economic
Area,  and  (d)  similar  extensions  under any applicable law in the Territory.

1.4     "DGI Technology" shall mean any proprietary know-how owned or controlled
by  DGI as of the Effective Date and/or developed, acquired or controlled by DGI
during  the  Term,  including  but  not  limited to technical data, experimental
results,  specifications,  techniques, inventions, processes, formulas and other
materials,  all of which are useful in the development, discovery, production or
use  of  Licensed Product.  DGI Technology shall not include; (a) know-how which
at  the  time of disclosure is in the public domain, (b) know-how which prior to
the  disclosure  was  in  Novo Nordisk's possession, and (c ) know-how developed
independently  by Novo Nordisk without any use of any DGI Technology whatsoever.

1.5     "Diogenesis" shall mean DGI's surrogate ligand-based approach to finding
and  using  site-directed  assays  to  identify  drug  leads.

1.6     "Field"  shall  mean  a  Product  useful  in  treating,  preventing  or
controlling diabetes by direct or indiret [*                           *],  the
development or discovery of which  utilizes  DGI  Technology and/or is  covered
by  a  DGI  Patent Right.

1.7     "First  Commercial  Sale"  shall mean the first sale or other commercial
disposal  by  Novo  Nordisk  or  its sublicensee, after the Effective Date, of a
Licensed  Product  for  value,  in  an  arm's length transaction, in any country
within  the  Territory.

1.8     "Improvement"  shall  mean  any modification, alteration, enhancement or
improvement  to  DGI  Patent  Rights and/or DGI Technology, which relates to the
Licensed  Product(s).

1.9     "IND"  shall  mean  an Investigational New Drug application submitted to
the  Food  and  Drug  Administration of the United States, and/or  an equivalent
application  to  the  equivalent  regulatory  body  in the European Union and/or
Japan.

1.10     "Licensed  Product"  shall  mean  Products  within  the  Field;
(a)     the manufacture and/or sale of which are covered by a Valid Claim of DGI
Patent  Rights,  and/or

                                      2
<PAGE>

"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

(b)     which  are  developed  utilizing  DGI  Technology.

1.11     "Major  Market"  shall  mean  the  United States, European Union and/or
Japan.

1.12     "NDA" shall mean a New Drug Application submitted  to the Food and Drug
Administration  of  the  United  States, and/or an equivalent application to the
equivalent  regulatory  body  in  the  European  Union  and/or  Japan.

1.13     "Net  Sales" shall mean Novo Nordisk's and its sublicensee's (s') gross
proceeds  from sales of Licensed Product invoiced to any independent third party
less,

i.     any  direct or indirect credits and allowances or adjustments, including,
without limitation, credits and allowances on account of price adjustments or on
account  of  rejection,  recall  or  return of Licensed Product previously sold;
ii.     any  trade  and cash discounts; price reductions or rebates, retroactive
or  otherwise,  imposed  by  government authorities; and third party distributor
fees;

iii.     any  sales,  excise,  turnover,  value  added, or similar taxes and any
duties  and other governmental charges imposed upon the production, importation,
use  or  sale  of  Licensed  Product(s);
iv.     applicable  transportation,  importation,  insurance  and other handling
charges,  and

v.     the  cost of special devices used for administration of Licensed Product.
Such  special  devices  shall  not  include  conventional devices (e.g. tablets,
standard  syringes,  suppositories  and/or  standard  transdermal  patches).
Deductions  i,  ii, and iv shall not exceed fifteen percent (15%) of gross sales
of  Licensed Product by Novo Nordisk and its sublicensee(s) during any reporting
period.

In  the event that the Licensed Product is sold as part of a Combination Product
the  Net  Sales of the Licensed Product, for the purposes of determining royalty
payments,  shall  be  determined by multiplying the Net Sales of the Combination
Product  (as defined in the standard Net Sales definition) by the fraction, A/(A
+  B)  where  A  is  the  average  sale  price of the Licensed Product when sold
separately  in  finished  form  and

                                      3
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

B  is the average sale price of the other product(s) sold separately in finished
form.
In  the  event  that  the  average  sale  price  of  the Licensed Product can be
determined  but  the  average  sale  price  of  the  other  product(s) cannot be
determined,  Net  Sales  for  purposes  of determining royalty payments shall be
calculated  by  multiplying  the  Net  Sales  of the Combination Products by the
fraction  C/(C  +  D)  where C is the selling party's average sales price of the
Licensed  Product  and  D is the difference between the average selling price of
the  Combination  Product and the average selling price of the Licensed Product.
If  the  average  sale  price  of the other product(s) can be determined but the
average  price  of  the  Licensed  Product  cannot  be determined, Net Sales for
purposes  of  determining royalty payment shall be calculated by multiplying the
Net  Sales  of  the Combination Products by the following formula: one (1) minus
C/(C  + D) where C is the average selling price of the other product(s) and D is
the difference between the average selling price of the Combination Products and
the  average selling price of the other product(s).  In no event, however, shall
the  Net  Sales of Licensed Products be less than fifty percent (50%) of the Net
Sales  of  the  Combination  Products.

In  the  event  that the average sale price of both the Licensed Product and the
other  product(s) in the Combination Product cannot be determined, the Net Sales
of  the  Licensed  Product shall be deemed to be equal to fifty percent (50%) of
the  Net  Sales  of  the  Combination  Product.
The  Net  Sales  price  for  a Combination Product shall be calculated once each
calendar  year  and  such  price  shall  be  used  during all applicable royalty
reporting  periods  for  the entire calendar year.  When determining the average
sale  price of a Licensed Product or product(s), the average sale price shall be
calculated  using  data  arising  from  the  twelve  (12)  months  preceding the
calculation  of the Net Sales price for the Combination Product.  As used above,
the  term "Combination Product" means any pharmaceutical product which comprises
the  Licensed  Product  and  other  active  compounds  and/or  ingredients.
1.14     "Novo Nordisk" shall mean Novo Nordisk A/S and/or any Affiliate thereof
which  is  a  party  to  the  arrangements  set  forth  in  this  Agreement.
1.15     "Novo  Nordisk  Patent Rights" shall mean rights to patent applications
and  patents  filed  by or on behalf of Novo Nordisk pursuant to this Agreement.

                                      4
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

1.16     "Parties"  shall  mean  DGI  and Novo Nordisk collectively and the term
"Party"  shall  mean  each  of  DGI  and  Novo,  Nordisk,  individually.

1.17     "Phase  II"  initiation  shall  mean  initiation  of clinical trials to
demonstrate  efficacy  and  short  term  safety.

1.18     "Phase  III"  initiation  shall  mean  initiation of clinical trials to
demonstrate  efficacy  and  safety  in  larger  patient  groups.

1.19     "PLPc"  shall mean Preclinical Lead Profile candidate as defined in the
prevailing  Novo Nordisk guidelines for management of Novo Nordisk's Health Care
Discovery  projects.

1.20     "Product"  shall  mean a molecule discovered and/or developed using DGI
Patent  Rights  and/or  DGI  Technology.

1.21     [**].
1.22     "Research  Plan"  shall  mean the research program to be carried out by
DGI as described in Section 6.3 and as included as Appendix B to this Agreement.

1.23     "Term"  shall  mean  the last to expire of a DGI or Novo Nordisk Patent
Right  containing  a  Valid  Claim,  covering  the  making,  using or selling of
Licensed  Product  or  twenty  (20)  years,  whichever  is  later.

1.24     "Territory"  shall  mean  all  countries  in  the  world.

1.25     [*    *]

2.     GRANT  OF  LICENSES

2.1     DGI  hereby  grants to Novo Nordisk, and Novo Nordisk hereby accepts, an
exclusive  license  within the Field under DGI Patent Rights and DGI Technology,
even  as  to  DGI,  including  the  right  to  sublicense, to use, produce, have
produced,  import,  offer  to sell, sell and/or co-promote and/or co-market with
one or more third parties, Licensed Products in the Territory subject to Section
2.3.  For the purpose of this Agreement, a co-promotor or a co-marketer shall be
considered  a  sublicensee.

                                      5
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

2.2     DGI hereby grants to Novo Nordisk, and Novo Nordisk hereby accepts, an
exclusive license  subject  to  Section 2.3, even as to DGI, to use and develop
DGI Patent Rights  and  DGI  Technology  within  the  Field.

2.3
(a)     DGI  shall  retain  a  royalty free right and license to use DGI
Technology,  either  alone  or  in  combination  with  others  to develop and [*
*}  povided  however  such  license  shall  be  limited  only  to  the  [*   *]

(b)     DGI  shall  keep Novo Nordisk informed of the progress of its [*      *]
on  a  regular  basis  and particularly if any significant results are observed,
provided  it  is  not  precluded from doing so by a commitment to a third party.

(c)     DGI  hereby  grants  to  Novo Nordisk, the first right of refusal for an
exclusive  license  to any [*                  *] DGI shall not offer a license
under  more  favorable  terms  to  a  third  party  unless first offered to Novo
Nordisk.

2.4     Any  improvements  within  the  Field,  made  conceived, obtained and/or
controlled  by  DGI  during  the Term shall be disclosed to Novo Nordisk without
further  financial obligation subject to Section 2.3.  Novo Nordisk may use such
DGI  improvements in connection with the Licensed Product by Novo Nordisk and/or
its  sublicensees  in  the  Territory.

3.     LICENSING  FEES,  MILESTONE  FEES  AND  ROYALTIES

3.1     As  compensation to DGI for the licenses granted hereunder and furnished
to Novo Nordisk, Novo Nordisk agrees to pay to DGI the license fees set forth in
Section  3.2, milestone fees set forth in Section 3.3 and royalties set forth in
Section  3.4.

3.2     Novo  Nordisk  shall  pay  the  following  license  fees  to  DGI:

(a)     Six Hundred Thousand U.S. Dollars (US $600,000) within ten (10) business
days  of  signing  of  this  Agreement  by  both  Parties;

(b)     Five  Hundred  Thousand  U.  S.  Dollars  (US  $500,000) within ten (10)
business  days  of  the  signing  of  this  Agreement  by  both  Parties,  and

                                      6
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

(c  )     Five  Hundred  Thousand  U.S.  Dollars  (US  $500,000) within ten (10)
business  days  of the one (1) year anniversary of the signing of this Agreement
by  both  Parties.

3.3     Novo  Nordisk  shall  pay  the  following  milestone  fees  to  DGI:
(a)     [*  *]:
i.      [*  .*]
ii.     [*  .*]
iii.    [*  *]
iv.     [*  *]
v.      [*  *]
vi.     [*  *]
vii.    [*  *]
(b)     [*  *]
i.      [*  *]
ii.     [*  *]
iii.    [*  *]
iv.     [*  *]

                                      7
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

v.      [*  *]
vi.     [*  *]
vii.    [*  *]

3.4.     Novo  Nordisk  shall  pay  DGI  a  royalty  based  upon  its  and  its
sublicensee's(s')  annual  Net  Sales of Licensed Products in the Territory, for
each  year  commencing  with  the  First  Commercial  Sale  and  terminating
[*                                      *]  The royalty shall be payable by Novo
Nordisk  on  annual  Net  Sales within the Territory, according to the following
rates:
(a)     [*   *]
i.      [*  *]
ii.     [*  *];  and
iii.    [*  *].
(b)     [*  *].

3.5     In  the  event Novo Nordisk experiences generic competition in excess of
twenty  percent  (20%),  in  a country of Novo Nordisk and its sublicensee's(s')
sales  of Licensed Product during any calendar quarter, as reflected in IMS data
and/or  documented  declines in governmental sales, then the  rate at which Novo
Nordisk  pays royalty in that country, shall be reduced by the same reduction of
market  share  as  the  generic  competition.

3.6     One-half  of the milestone fee payments, set forth in Section 3.3, shall
be  credited  against  the royalty payments under Section 3.4.  However, in each
year  referred  to  in  Section  3.4,  Novo  Nordisk  shall  not  deduct

                                      8
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

more  than  fifty  percent  (50%)  of the royalties due under Section 3.4.  Novo
Nordisk  shall  continue to take a credit against royalty payments until the sum
of  the  milestone  fees  has  been  fully  credited.

3.7     Novo  Nordisk  shall pay only one royalty under Section 3.4 on Net Sales
of  Licensed  Product,  notwithstanding  the number of patents within DGI Patent
Rights and/or the nature and/or amount of DGI Technology.  Once Novo Nordisk has
made  one  or  more  milestone  payments for a molecule, such milestone payments
already  paid  need not be paid for another molecule selected for development in
place  of  the  first  mentioned  molecule,  unless such molecule is to be taken
independently  to  the  market.

3.8     Sales  of  Licensed Product between Novo Nordisk, its Affiliates and its
sublicensees shall not be subject to any royalty obligation.  In such cases, the
royalty  shall  be  calculated  upon  Novo  Nordisk's  or its Affiliate's or its
sublicensee's  Net  Sales  to  an  independent  third  party.

3.9     (a)     If  Novo  Nordisk  grants  a  sublicense,  all  of the terms and
conditions  of  this Agreement shall apply to the sublicensee to the same extent
as  they apply to Novo Nordisk for all purposes of this Agreement.  Novo Nordisk
assumes responsibility for the performance of all obligations so imposed on such
sublicensee  and  will itself pay and account to DGI for all royalties due under
this  Agreement  by  reason  of  the  operations  of  any  such  sublicensee.
(b)     Novo  Nordisk  may  extend  to any of its Affiliates the benefit of this
Agreement,  but  Novo  Nordisk  shall  remain  responsible to DGI for all of the
obligations  placed  upon  Novo  Nordisk  by  this  Agreement.

4.     PAID  UP  LICENSE

4.1     Novo  Nordisk's  obligations  to  pay royalties, under section 3.4 shall
expire  on a country-by-country basis upon the later of ten (10) years after the
First  Commercial  Sale  of  Licensed  Product  and expiration of the DGI Patent
Rights.

4.2     Upon  the expiration of Novo Nordisk's obligation to pay royalties, Novo
Nordisk  shall have a fully paid-up license to use, produce, offer to sell, sell
and/or  co-promote  and/or  co-market  with  one or more third parties under DGI
Patent  Rights  and  DGI  Technology.

5.     REMITTANCES  AND  AUDITS

5.1     Novo  Nordisk  shall  make  all  payments  to  DGI under this Agreement,
according  to  its  terms.  If  any  payments  made  by  Novo  Nordisk  under

                                      9
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

this  Agreement  is  subject  to  withholding tax, such withholding tax shall be
borne  by  DGI and shall be deducted from the payments made by Novo Nordisk.  As
long  as  DGI  provides Novo Nordisk with all the necessary documentation (i.e.,
special  Danish Tax Form, IRS Form 1001, and relevant equivalents), Novo Nordisk
shall,  with respect to applicable laws support DGI in its efforts of minimizing
the  withholding  taxes.  In the event that Novo Nordisk does deduct or withhold
any  such  taxes,  as soon as practical, Novo Nordisk shall submit to DGI proper
documentation  confirming  Novo  Nordisk's  payment  of any such taxes for DGI's
account.

5.2     All  royalty  payments  under  this  Agreement  shall be due and payable
within  sixty  (60)  days after the last day of each calendar quarter, beginning
with  the  calendar  quarter  in  which  the  First  Commercial  Sale  occurred.

5.3     Novo Nordisk shall, within (60) days after the last day of each calendar
quarter, beginning with the quarter in which the First Commercial Sale occurred,
provide  DGI  a  written  statement,  showing  all  Net  Sales by country in the
Territory.  In case no royalty is due for any such period, Novo Nordisk shall so
report.

5.4     All  payments  of  royalties  shall be made in United States Dollars and
such payments shall be made via wire transfer to one or more bank accounts to be
designated  in  writing,  prior  to  the  First  Commercial Sale, by DGI to Novo
Nordisk.  In  the  event  that  any  Net Sale is made in a foreign currency, the
amount  of  such  Net  Sale  shall  be converted to United States dollars at the
exchange  rate  set  forth  in  the Wall Street Journal (Eastern Edition).  This
conversion  shall be made using an average quarterly exchange rate determined as
the  average of the exchange rates set forth in the Wall Street Journal (Eastern
Edition)  published  during  the  applicable  reporting  calendar  quarter,  if
available,  and  otherwise  using  rates as announced by the central bank of the
subject  country  of  the  Territory.

5.5     For  the Term and for two (2) years thereafter, Novo Nordisk shall keep,
and  shall cause its sublicensee(s) selling Licensed Product in the Territory to
keep,  complete  and accurate records of Net Sales of Licensed Product.  Records
shall be kept in sufficient detail to enable the determination of royalties due,
under  Section  3.4  hereof.

5.6     During  the  Term  and  for two (2) years thereafter, Novo Nordisk shall
give  access  to a nationally-recognized independent certified public accountant
("DGI Accountant"), appointed and paid by DGI, to which/whom Novo Nordisk has no
reasonable  objection,  to  such

                                      10
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

records of Novo Nordisk as described in Section 5.5, within two (2) years of the
royalty period to which the records apply, in order to permit the DGI Accountant
to  verify  the  accuracy  of  any  royalty  payments made or payable under this
Agreement.  Such access shall be granted no more than once in any calendar year,
at DGI's request, during regular business hours and with ten (10) business-days'
notice.  The  DGI Accountant shall be under a confidentiality obligation to Novo
Nordisk  to  disclose  to  DGI, in such Accountant's report, only the amount and
accuracy of royalty payments made or payable under this Agreement.  In the event
the  amount  payable under this Agreement is more than that actually paid to DGI
by  Novo  Nordisk  (except  for  amounts  not  yet  due  on  Net  Sales  for the
immediately-past  calendar  quarter),  Novo Nordisk shall pay such difference to
DGI  within  thirty  (30)  days  of  such  DGI  Accountant's  report.
5.7     If  in  any  country,  the  transfer of royalties provided for herein is
prohibited  by  law or regulation, Novo Nordisk shall remit the royalty in local
currency  to  an interest bearing account in the name of DGI with banks or other
financial  institutions  located  in  such  country  as  designated  by  DGI.

6.     DEVELOPMENT  AND  REGISTRATON

6.1     [*                                  *]  Novo  Nordisk  shall  conduct,
at its expense, any pre-clinical and  clinical trials necessary to receive and
maintain registrations to sell any Licensed  Products(s)  in  the  Territory.

6.2     Novo  Nordisk  shall  obtain and maintain, at its sole cost and expense,
all  permits,  licenses,  authorizations  and  registrations  for  any  country,
sovereignty,  state,  country, parish, municipality, or other local governmental
entity  in  the  Territory  which  are  necessary  for  Novo  Nordisk to import,
distribute  and  sell  Licensed  Product.

6.3     DGI  shall  allocate the equivalent of one full time employee to conduct
further  research  on behalf of Novo Nordisk.  Such research shall commence upon
both  Parties  mutually  agreeing  upon  the  research  to

                                      11
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

be  conducted,  as  outlined  in  the  Research  Program  in  Appendix B of this
Agreement.  Such  research  shall  be  performed at a cost of One Hundred Eighty
Five  Thousand U.S. Dollars (US $185,000).  Such payment shall be made to DGI on
a  quarterly basis.  During the Research Program; (i) an exchange of information
shall occur on an ad hoc basis between scientists, and (ii) at the conclusion of
the  Research  Program,  DGI  shall  submit a report to Novo Nordisk stating all
results  of  the  Research  Program.  Upon  the completion of said research, the
Parties  shall  mutually  decide  whether  further  work  is  necessary.

6.4
(a)     A Steering Committee shall be established.  Novo Nordisk and DGI
shall  each  appoint their members (one, maximum two) to the Steering Committee.
However,  each  Party may bring as many representatives of its organization to a
meeting  of  the  Steering  Committee  as  it  chooses.

(b)     The  Steering  Committee  shall  be  responsible  for  the  following:
i.     overseeing  execution of the Research Plan to be performed referred to in
Section  6.3  of  this  Agreement;
ii.     review  and report all DGI Technology being transferred to Novo Nordisk;
iii.     review  and  comment  on  all patent applications to be filed by either
Party  which  are  related  to  the  Field;
iv.     perform  such  other  duties  as  the  Parties  mutually agree upon; and
v.     determining  which  new  technologies, know-how, inventions identified by
each  Party,  will  become  part  of  Appendix  C  of  this  Agreement.

(c)     The Steering Committee shall make decisions by making a resolution, such
resolution  being  passed  unanimously.  All  decisions, resolutions and matters
discussed  at the Steering Committee shall be stated in minutes approved by both
Parties.  Should  the  Steering  Committee  not  be  able  to  make  a unanimous
decision, the matter shall be referred to the Corporate Vice President of Health
Care  Discovery  at  Novo  Nordisk  and  to  the  President  of  DGI.

(d)     The  Steering  Committee  shall  determine  all  matters of a procedural
nature  for  the  conduct  of  its  meetings,  including  but

                                      12
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

not  limited  to,  place, frequency and  form.  The first meeting ofthe Steering
Committee  shall  take  place no later than thirty (30) days after the execution
date  of  this  Agreement.

7.     TECHNICAL  INFORMATION  AND  KNOW-HOW
During  the  Term,  DGI  shall  disclose  and  furnish  to  Novo Nordisk all DGI
Technology  developed  with  the  use  of  the [*     *]  and controlled by DGI
during  the  Term  subject  to  Section  2.3.

8.     MARKETING  AND  PROMOTION
Novo  Nordisk  shall  employ  resources  in  developing, registering, promoting,
marketing  and  selling  Licensed  Products in the Territory that are consistent
with  its  activities  with  respect to its other products of similar commercial
potential and product profile, and it shall be solely responsible for developing
and  implementing  a  marketing  plan  for the Licensed Products.  All costs and
expenses in connection with the marketing, advertising and promoting of Licensed
Products  in  the  Territory  shall  be  borne  by  Novo  Nordisk.

9.     PATENTS

9.1     DGI  Patent  Rights  shall  be  maintained  and  prosecuted by DGI.  The
Parties  shall  mutually  agree  on patent counsel [*         *].  The fees and
expenses including, without limitation, filing, prosecution and maintenance fees
and  the fees and expenses of such patent counsel shall be paid by [*  *].  Any
additional  countries  which [*    *] filing, shall be approved by both Parties.
[*             .*]

9.2     At  least every six months and prior to filing of any DGI Patent Rights,
DGI  shall  provide  to Novo Nordisk an update on the status and progress of the
filing,  prosecution  and  maintenance  of  all  patents and patent applications
within  DGI  Patent  Rights.  DGI  agrees  to  provide  copies  of all documents
received  from  the relevant patent offices in relation to all DGI Patent Rights
and  further  agrees  to  provide  Novo

                                      13
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

Nordisk  with  advance  copies  of  any  papers  to  be filed in a patent office
relating  to  DGI Patent Rights with sufficient time for Novo Nordisk to provide
its  comments  to  DGI  before  the  filing  of  said  papers.

9.3     Novo  Nordisk shall have the right to file patents based upon DGI Patent
Rights, DGI Technology and/or the Licensed Product resulting from Novo Nordisk's
research  and  development.  Such  patents shall be known as Novo Nordisk Patent
Rights  which  are  to  be  maintained, prosecuted and paid for by Novo Nordisk.

9.4     Without  limiting  the  forgoing,  each  Party will have all rights of a
joint  owner  under  any  joint patents or other inventions made jointly by both
Parties  ("Joint Patent Rights").  DGI agrees that Novo Nordisk shall be granted
an  exclusive license, even as to DGI, including the right to sublicense, to use
Joint  Patent  Rights  within the Field.  The use of Joint Patent Rights outside
the  Field  shall  be  mutually  agreed  by both Parties.  Inventorship shall be
determined  according  to  US  law.   Joint  Patent  Rights shall be maintained,
prosecuted  and  paid  for  by  Novo  Nordisk.

9.5     Except  as  otherwise  explicitly licensed as provided herein each Party
will,  as  between  it  and  the other Party hereto, retain ownership of its own
inventions,  copyrights,  trade  secrets,  patent  rights  and other technology.

9.6     All  trademark  and service mark rights and all goodwill associated with
any  trademarks  and  service  marks used by Novo Nordisk and its Affiliates and
sublicensees  in  connection  with Licensed Products shall belong solely to Novo
Nordisk.

9.7     The  Parties  shall  furnish  to  the other Party copies of any proposed
publication  and/or  presentation of results relating to the Field in advance of
the  submission  of  such proposed publication and/or presentation to a journal,
editor  or  other  third  party.  The  receiving Party shall have two (2) months
after  receipt  of  said  copies  to object to such proposed presentation and/or
proposed  publication  because  there  is  patentable  subject  matter  or other
confidential  information  which  needs  protection.  In  the  event,  that  the
receiving  Party  objects,  the  other  Party  shall  refrain  from  making such
publication  and/or  presentation  for  a maximum of six (6) months from date of
receipt  of  such  objection.  In  no  event,  shall  either Party be allowed to
publish  and/or  present the peptide sequences and motifs and the other Parties'
confidential  or  proprietary  information  without  prior  written  approval.

                                      14
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

10.     INFRINGEMENT  OF  DGI  PATENT  RIGHTS

10.1     Each  Party  shall advise the other promptly upon becoming aware of any
infringement  by  a  third  party  of  DGI  Patent  Rights.

10.2     Novo  Nordisk  shall  at  Novo Nordisk's sole discretion, but including
discussion  with  DGI,  take  such  legal action as is required to restrain such
infringement.  DGI  shall  cooperate  fully with Novo Nordisk, at Novo Nordisk's
request,  in  Novo  Nordisk's  effort to restrain such infringement.  DGI may be
represented  by  counsel  of its own selection at its own expense in any suit or
proceeding brought to restrain such infringement but Novo Nordisk shall have the
right  to  control the suit or proceeding. Any recovery obtained by Novo Nordisk
as  a  result  of  such suit or proceeding whether by judgment, award, decree or
settlement  shall  be  first  used  to  reimburse Novo Nordisk for its costs and
expenses  pursuing  such  suit or proceeding, and the remaining balance shall be
split  in  the  following  manner:  [*                 *].

10.3     If  Novo  Nordisk  elects not to initiate an infringement action within
sixty  (60)  days  of the mutual agreement of the Parties as to the existence of
infringement  of  DGI  Patent  Rights,  DGI  shall  have  the right, in its sole
discretion,  to institute such action, at DGI's own expense. In such event, Novo
Nordisk shall fully cooperate with DGI. Any recovery received by DGI as a result
of  such  suit  or  proceeding  whether by judgment, award, decree or settlement
shall  first  be used to reimburse DGI for it's costs and expenses pursuing such
suit  or  proceeding,  and  the  remaining  balance  shall  be  [*          *].

11.     WARRANTIES  AND  REPRESENTATIONS

11.1     DGI warrants and represents that it owns all rights, title and interest
in  and  to  the  DGI  Patent  Rights  and  DGI Technology, exclusively licensed
hereunder  to Novo Nordisk for the Territory, and that it has the full right and
authority  to license the rights granted to Novo Nordisk hereunder.  DGI further
warrants  and  represents that, to the best of its knowledge, each patent within
DGI  Patent Rights is valid and enforceable, and that each patent resulting from
a  patent  application  therein  shall  be  valid  and  enforceable.

11.2     Each  party  hereby  represents,  warrants and further covenants to the
other  that:

(a)     It  has  full  authority  to enter this Agreement in accordance with the
terms  of  this  Agreement;

                                      15
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

(b)This Agreement is not in conflict with any other agreements to which it
 is party  or  by  which  it  may  be  bound;

(c)     This  Agreement  when  executed shall become the legal valid and binding
obligation  of  it, enforceable against it, in accordance with its terms, except
as  enforceability  may  be limited by bankruptcy, insolvency, reorganization or
other  similar  laws  relating  to  the  rights  of  creditors  generally;  and

(d)     It  shall  negotiate in good faith the execution of such other documents
or  agreements  as  may be necessary or desirable for the implementation of this
Agreement  and  the effective execution of the transactions contemplated hereby.

12.     INDEMNIFICATION

12.1     Each  Party  shall  defend,  indemnify and hold the other Party and its
shareholders,  directors,  officers,  employees  and  agents  harmless  from and
against any and all claims, judgments, causes of action, costs, awards, expenses
(including  attorneys'  fees and (other) expenses of litigation), arising out of
the  indemnifying  Party's  activities  under  this  Agreement,  including,  as
applicable,  the manufacture, importation, use, promotion, marketing and/or sale
of  Licensed  Product,  unless  such  liability  results  from  a  breach of the
indemnified Party's negligence or willful misrepresentations or other misconduct
or  a  breach  of  the  indemnified  Party's warranties set forth in Section 11.

12.2     One  Party shall promptly notify the other Party of any claims or suits
for  which  said  one  Party  may  assert  indemnification from said other Party
hereunder  and  said one Party shall permit said other Party, or its insurer, at
said  other Party's expense, to assume or participate in the defense of any such
claims  or suits and said one Party shall cooperate with said other Party or its
insurer  in  such  defense when reasonably requested to do so.  No settlement or
compromise shall be binding on a Party hereto without its prior written consent.

13.     CONFIDENTIALITY  AND  NON-DISCLOSURE

13.1      During  the  Term,  DGI and Novo Nordisk may receive or have access to
information  that  is  confidential  and  proprietary  to the other Party (as to
either  party,  its  "Information"),  the  maintenance  of  the  secrecy  and
confidentiality of which is acknowledged by each Party to be important.  For the
purpose  of  this  Section,  "Recipient"  refers  to  the  Party  receiving  the
Information  from  Discloser  and "Discloser" refers to the Party disclosing the
Information  to  Recipient.  Information  includes proprietary  and confidential
matters  concerning  certain  know-how,

                                      16
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

data  and/or  other  matters  related to the Discloser's current and/or proposed
product(s),  including  but  not  limited  to research, products, clinical data,
insulin  receptor,  developments,  inventions,  processes,  technology, security
controls,  marketing,  finances and pricing.  Confidential Information shall not
include  information  which:  (i)  is known to the Recipient or is independently
generated  by  or  for Recipient without benefit of the Discloser's Confidential
Information;  (ii)  is  disclosed  to  the Recipient, without restriction, by an
independent  third  party having a legal right to make such disclosure; (iii) is
or  becomes  part  of  the  public domain through no breach of this Agreement by
Recipient; or (iv) the Recipient is required to disclose to relevant authorities
in  connection  with  its development or commercialization of a PLPc or Licensed
Product  pursuant  to  this  Agreement.

13.2     During  the Term and for five (5) years thereafter, Recipient (i) shall
not,  without  the Discloser's prior written consent, disclose, use or permit to
be  used  the  other  Party's  Information  in  any  manner  except as expressly
authorized by this Agreement (ii) shall treat such Information with at least the
same  degree  of care that it treats its own confidential information, but in no
event  with  less  than  a  reasonable  degree  of care, and (iii) shall use its
reasonable  best  efforts  to  prevent disclosure of Information to unauthorized
parties.  Recipient  shall ensure that only its employees, authorized agents, or
subcontractors  or  vendors  who need to know the other Party's Information will
receive  such Information from Discloser and that such persons shall be bound to
Recipient  to  the  extent  that  Recipient  can honor its obligations under the
provisions  of  this  Section  13.  Upon demand, or upon the termination of this
Agreement, the Parties shall comply with each other's instructions regarding the
disposition  or return of each other's Information in its possession or control.

13.3     Unless  otherwise  required  by  law, neither Party shall use the name,
trademark  or  logo  of the other Party in any marketing, advertisement or other
publication,  shall  not  make any public statement relating to the other Party,
and  will  not  release  or  disclose  any  information concerning the terms and
conditions  of  this  Agreement  to  any  third party, without the prior written
consent of the other Party, or as required to register, promote or sell Licensed
Product.

14.     COMPLIANCE  WITH  LAWS
Each Party hereto agrees that it shall comply with all applicable international,
country  and  local  laws,  ordinances  and  codes in performing its obligations
hereunder,  including  the  procurement  of sublicenses, permits, certificates,

                                      17
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

registrations  and  any  other  requirements  necessary  to  comply  with  this
Agreement.  If  at any time during the Term, a Party is informed, or information
comes to its attention, that it is or may be in violation of any law, ordinance,
regulation  or  code  with respect to its activities hereunder, that Party shall
immediately  take  all appropriate steps to attempt to remedy such violation and
comply  with  such law, regulation, ordinance or code in all respects.  Further,
each  Party  shall establish and maintain all proper records required by any law
or  code  of  practice  applicable  to  it  from  time  to  time.

15.     NOTICES

15.1     Any  notice  required  to  be given pursuant to this Agreement shall be
made  in  writing  and shall be deemed to have been duly given if delivered by a
recognized  commercial courier service with receipt acknowledged, telefaxed with
receipt  acknowledged  (and  with  a  confirmation copy sent by registered mail,
return  receipt  requested),  or  mailed by registered or certified mail, return
receipt  requested,  postage  prepaid,  as  follows:

     If  to  Novo  Nordisk               Novo  Nordisk  A/S
                                         Novo  Alle
                                         2880  Bagsvaerd
                                         Denmark
                          Attention:     Corporate  Vice  President  of
                                         Health  Care
                                         Fax:     011-45-4442-7280

With  copy  to:                          Novo  Nordisk  A/S
                                         Novo  Alle
                                         2880  Bagsvaerd
                                         Denmark
                          Attention:     Legal  Department
                                         General  Counsel
                               Fax:      011-45-4498-0670

If  to  DGI                              DGI  BioTechnologies,  LLC
                                         40  Talmadge  Road
                                         P.O.  Box  424
                                         Edison,  NJ  08818
                          Attention:     Dr.  Arthur  J.  Blume,  President
                                Fax:     732-287-1486

With  copy  to:                          Gibbons,  Del  Deo,  Dolan,
                                         Griffinger  &  Vecchione
                                         One  River  Front  Plaza

                                      18
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

                              Newark,  NJ  07102
                    Attention:     Bernard  S.  Leon,  Esq.
                            Fax:     973-639-6461

16.     GOVERNING  LAW
This  Agreement  shall  be  deemed  to be a contract made under and construed in
accordance  with  the  laws  of  the  State  of  New York, without regard to its
conflicts  of  laws  principles.  The  Parties  agree  that all disputes will be
adjudicated  in Federal Court with both Parties agreeing to waive trial by jury.

17.     DISPUTE  RESOLUTION

17.1     In  the  event  of any dispute or disagreement between the Parties with
respect to the interpretation of any provision of this Agreement or with respect
to  the  performance  by DGI or by Novo Nordisk of its duties hereunder, each of
the  Parties  shall  appoint  a  designated  employee to meet for the purpose of
endeavoring  to  resolve  such dispute or to negotiate for an adjustment to such
provision.

17.2     In  the  event, an amicable resolution is not possible the Parties will
mutually  agree  to  non-binding  mediation.

17.3     Formal proceedings in Federal Court may only commence after the Parties
have  made  a  good  faith attempt to resolve their dispute during a non-binding
mediation  proceeding.

18.     TERM

This  Agreement  shall  become  effective  as  of  the  Effective Date and shall
continue  through  the  Term,  unless  sooner  terminated  as  provided  in this
Agreement.

19.     TERMINATION

19.1     This  Agreement  may  be  terminated  with the written approval of both
Parties  or  upon default as provided in Section 19.2 of this Agreement.  In the
event  such  termination  occurs  prior  to  the  payment of the license fees in
Section  3.2 of this Agreement, Novo Nordisk will be required to make payment of
such  license  fees  to  DGI  on  the  notice  of  such  termination.

19.2     If  either  Party  at  any  time  materially defaults (i) in making the
payment  of  any  money  due  hereunder,  or (ii) in fulfilling any of the other
obligations  or conditions hereunder, the other Party may in its sole discretion
waive  the  default;  if  not  electing  to  waive  the  default,  the

                                      19
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

other  Party  shall  notify  the  defaulting Party in writing of the default and
allow  the  defaulting Party ninety (90) days from such notification to initiate
reasonable  steps  to  cure such default.  Notwithstanding this section 19.2, if
the defaulting Party disputes the existence, nature or extent of any default set
forth  above,  the  Parties  shall use good faith efforts to resolve the dispute
pursuant to Article 17.  This Agreement shall continue until a final decision is
reached  pursuant  to  Article  17.

19.3     Either  Party  may  terminate  this  Agreement by written notice to the
other  Party  in  the  event  the  other  Party:

(a)     become  insolvent  or  bankrupt;

(b)     make  an  assignment  for  the  benefit  of  its  creditors;

(c)     appoint  a  trustee or receiver for itself for all or a substantial part
of  its  property;

(d)     have  any  case  of  proceeding  commenced  or  other action taken by or
against  itself  in  bankruptcy  that is not dismissed within sixty (60) days of
filing;  or

(e)     seeks  reorganization,  liquidation,  dissolution,  a  winding-up

arrangement,  composition or readjustment of its debts or other relief under any
bankruptcy,  insolvency,  reorganization  or  other  similar  act  or law or any
jurisdiction,  now  or  hereafter  in  effect.

19.4     Upon  any  termination  of this Agreement, other than the expiration of
the  Term,  if Novo Nordisk terminates in accordance with Section 19.3 or DGI is
considered  to  be  the  defaulting  Party  pursuant  to  Articles  17  and 19,
[*              *]  and  DGI  shall reconvey to Novo Nordisk all Novo Nordisk's
confidential  and  proprietary  information.    In  the  event, Novo Nordisk is
considered to be the defaulting  Party  pursuant  to  Article  17  and  19[*
                   *] In addition, DGI and Novo Nordisk shall negotiate in good
faith a license for Novo Nordisk's Patent  Rights, confidential and proprietary
information within the  Field.

20.     ASSIGNMENT

20.1     DGI  shall  notify  Novo  Nordisk  with  thirty (30) days prior written
notice,  in the event of a sale, assignment or transfer of its rights, title and
interest  in,  to  and  under  this  Agreement  to  any  parent,  subsidiary,

                                      20
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

affiliate  or  controlled  corporation  of  corporations  not within its current
structure  or  to any successor by consolidation, merger or the corporate action
or  to  a  corporation  or  other  business entity to which it may sell all or a
percentage  of  it's  assets.

20.2     In  addition,  all  Novo  Nordisk Information shall be returned to Novo
Nordisk  prior  to  such  assignment.  The  assignee  shall have no access to or
rights in any Novo Nordisk Information and/or Novo Nordisk Patent Rights.  It is
expressly understood and agreed, that any assignee of any rights hereunder shall
remain  bound  by  the  obligations  hereof.

20.3     Neither Party may assign this Agreement except to a party acquiring all
or  substantially  all of the assigning Party's business to which this Agreement
relates  without  the  prior  written  consent of the other Party, which consent
shall  not  be  unreasonably  withheld.  Notwithstanding this Section 20.3, Novo
Nordisk  may  assign  this  Agreement without receiving prior written consent of
DGI,  to  any  of its Affiliates.  Notwithstanding Section 20.1 and this Section

20.3,  DGI  shall  not  assign,  sell  and/or  transfer in whole or in part this
Agreement  to  Eli  Lilly  Co.,  Pfizer  and  Hoechst and/or their affiliates or
divisions,  without  the  prior  written  consent  of  Novo  Nordisk.

21.     SUCCESSORS

This  Agreement  binds  the  heirs,  executors,  administrators,  successors and
assigns  of  the  respective  parties  with respect to all covenants herein, and
cannot  be  changed  except  by  written  agreement  signed  by  both  Parties.

22.     SEVERABILITY

Any  provision  of  this  agreement  which  is  prohibited, unenforceable or not
authorized in any jurisdiction shall, as to such jurisdiction, be ineffective to
extent  of  such  prohibition,  unenforceability  or  non-authorization  without
invalidating  the  remaining  provisions  hereof  or  affecting  the  validity
enforceability  or  legality  of  such  provision  in  any  other  jurisdiction.

23.     FORCE  MAJEURE

Neither of the Parties hereto shall be liable in any manner for failure or delay
in  fulfillment of all or part of this Agreement, directly owing to acts of God,
governmental orders or restrictions, war, war-like conditions, revolution, riot,
looting,  strike,  lockout,  fire, flood or other causes or circumstances beyond
the  Parties'  control.

                                      21
<PAGE>
"Omitted Information filed separately with SEC-Confidential Treatment Requested
       by New Brunswick Scientific Co., Inc." and indicated as [*     *]

24.     ARTICLE  HEADINGS  AND  SECTION  REFERENCES

The  Article  headings  contained herein are for reference only and shall not be
considered  a  part  of  this  Agreement,  nor  shall they in any way affect the
interpretation  thereof.  Unless  otherwise specified herein,  all references in
this  Agreement  to  sections  are  to  Sections  of  this  Agreement.

24.     COMPLETE  AGREEMENT

This  Agreement  supersedes  any  and  all agreements, contracts or negotiations
relating  to the Licensed Product in the Territory.  This Agreement is entire in
itself  and  cannot  be  changed or terminated orally.  No modifications of this
Agreement  shall be binding unless signed by the Party against whom it is sought
to  be  enforced.  This  Agreement,  together  with  the appendices shall be the
entire  agreement and express the complete, exclusive and final understanding of
the  Parties  with  respect  to subject written approval herein and shall not be
altered, amended or modified except in a writing incorporated hereto, and signed
by  the  Parties.

     IN  WITNESS  WHEREOF, Novo Nordisk and DGI have caused this Agreement to be
executed  by  their  duly  authorized  officers.

NOVO  NORDISK  A/S                              DGI  BIOTECHNOLOGIES,  LLC.

BY:_____________________                    BY:_____________________
MADS  KROGSGAARD  THOMSEN

TITLE:  CORPORATE  VICE  PRESIDENT          TITLE:____________________
     OF  HEALTH  CARE  DISCOVERY
DATE:___________________                    DATE:____________________

                                      22
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]